Alembic Pharmaceuticals Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Alembic Pharma's Q4 FY26 revenue hit INR 1,838 Cr (+4% YoY), with PAT at INR 203 Cr. Full-year FY26 saw 10% revenue growth, PAT up 16% to INR 675 Cr. FY27 outlook targets low double-digit consolidated top-line growth, with US generics (10-15%), ROW (15%+), and API (~10%) leading. New US branded business (Pivya) scaling up, anticipating 100-150 bps margin drag for 1-2 quarters, offset by core business. R&D at INR 750-800 Cr, targeting high-value products. Emphasis on execution, growth quality, and margin improvement reflects a confident FY27 outlook.